JP2011511810A5 - - Google Patents

Download PDF

Info

Publication number
JP2011511810A5
JP2011511810A5 JP2010546107A JP2010546107A JP2011511810A5 JP 2011511810 A5 JP2011511810 A5 JP 2011511810A5 JP 2010546107 A JP2010546107 A JP 2010546107A JP 2010546107 A JP2010546107 A JP 2010546107A JP 2011511810 A5 JP2011511810 A5 JP 2011511810A5
Authority
JP
Japan
Prior art keywords
alkyl
item
amino
substituents
hydroxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2010546107A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011511810A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2009/033822 external-priority patent/WO2009102805A1/en
Publication of JP2011511810A publication Critical patent/JP2011511810A/ja
Publication of JP2011511810A5 publication Critical patent/JP2011511810A5/ja
Withdrawn legal-status Critical Current

Links

JP2010546107A 2008-02-11 2009-02-11 インドール化合物およびその使用方法 Withdrawn JP2011511810A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2782508P 2008-02-11 2008-02-11
PCT/US2009/033822 WO2009102805A1 (en) 2008-02-11 2009-02-11 Indole compounds and methods of use thereof

Publications (2)

Publication Number Publication Date
JP2011511810A JP2011511810A (ja) 2011-04-14
JP2011511810A5 true JP2011511810A5 (cg-RX-API-DMAC7.html) 2012-04-05

Family

ID=40445507

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010546107A Withdrawn JP2011511810A (ja) 2008-02-11 2009-02-11 インドール化合物およびその使用方法

Country Status (6)

Country Link
US (1) US20090318527A1 (cg-RX-API-DMAC7.html)
EP (1) EP2254865A1 (cg-RX-API-DMAC7.html)
JP (1) JP2011511810A (cg-RX-API-DMAC7.html)
AU (1) AU2009214724A1 (cg-RX-API-DMAC7.html)
CA (1) CA2715282A1 (cg-RX-API-DMAC7.html)
WO (1) WO2009102805A1 (cg-RX-API-DMAC7.html)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006047032A2 (en) * 2004-09-27 2006-05-04 Organix, Inc. Indole compounds useful as serotonin selective agents
WO2011014128A1 (en) * 2009-07-30 2011-02-03 National University Of Singapore Small molecule inhibitors of isoprenylcysteine carboxyl methyltransferase with potential anticancer activity
US8912220B2 (en) 2009-08-10 2014-12-16 Galenea Pharmaceuticals Compounds and methods of use thereof
WO2015066344A1 (en) 2013-11-01 2015-05-07 Arena Pharmaceuticals, Inc. 5-ht2c receptor agonists and compositions and methods of use
EP3519816A4 (en) * 2016-09-29 2020-05-06 The Regents of the University of California CONNECTIONS FOR INCREASING NEURONAL PLASTICITY
GB2571696B (en) 2017-10-09 2020-05-27 Compass Pathways Ltd Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced
WO2020072675A1 (en) 2018-10-02 2020-04-09 Northwestern University Beta-carbolines as positive allosteric modulators of the human serotonin receptor 2c (5-ht2c)
KR102946120B1 (ko) 2019-02-27 2026-03-30 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 뇌 장애를 치료하기 위한 아제피노-인돌 및 다른 헤테로사이클
US12616706B2 (en) 2019-03-07 2026-05-05 Arbormentis LLC Compositions and methods of use comprising substances with neural plasticity actions administered at non-psychedelic/psychotomimetic dosages and formulations
KR20220008824A (ko) 2019-04-17 2022-01-21 컴퍼스 패쓰파인더 리미티드 실로시빈으로 불안 장애, 두통 장애 및 섭식 장애를 치료하는 방법
US20230021957A1 (en) * 2019-12-04 2023-01-26 Neonmind Biosciences Inc. Use of psilocin, psilocybin or analogs thereof in weight loss, treatment of obesity and compulsive eating disorder
MX2022009527A (es) * 2020-02-04 2022-11-16 Mindset Pharma Inc Derivados de la psilocina como agentes psicodelicos serotoninergicos para el tratamiento de trastornos del snc.
IL312785B2 (en) 2020-05-19 2026-06-01 Cybin Irl Ltd Deuterated tryptamine derivatives and methods of use
CA3201913A1 (en) 2020-12-09 2022-06-16 Andrew R. Chadeayne Dialkyl trytamines and their therapeutic uses
WO2022221415A2 (en) 2021-04-13 2022-10-20 The Regents Of The University Of California Tetracyclic compounds for treating brain disorders
WO2022246554A1 (en) * 2021-05-26 2022-12-01 Bright Minds Biosciences Inc. Heterocyclic compounds and methods of preparation thereof
CA3244229A1 (en) * 2021-12-24 2023-06-29 Psylo Pty Ltd COMPOUNDS
US12065404B2 (en) 2022-03-18 2024-08-20 Enveric Biosciences Canada Inc. C4-carboxylic acid-substituted tryptamine derivatives and methods of using
CA3261749A1 (en) * 2022-07-15 2024-01-18 Caamtech, Inc. TRYPTAMINE DERIVATIVES
AU2023323907A1 (en) * 2022-08-11 2025-02-20 Gilgamesh Pharmaceuticals, Inc. Tryptamines and methods of treating mood disorders
WO2024052895A1 (en) 2022-09-06 2024-03-14 Hadasit Medical Research Services And Development Ltd Combinations comprising psychedelics for the treatment of schizophrenia and other neuropsychiatric and neurologic disorders
EP4735441A1 (en) 2023-06-28 2026-05-06 Psylo Pty Ltd Pyrrolopyridine compounds for the treatment of mental illnesses
JP2026524104A (ja) 2023-06-28 2026-07-17 サイロ プロプリエタリー リミテッド 化合物
WO2025099725A1 (en) 2023-11-09 2025-05-15 Hadasit Medical Research Services And Development Ltd. Conjugates and uses thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2566056T3 (es) * 2001-03-29 2016-04-08 Eli Lilly And Company N-(2-ariletil)bencilaminas como antagonistas del receptor 5-HT6
WO2006047032A2 (en) * 2004-09-27 2006-05-04 Organix, Inc. Indole compounds useful as serotonin selective agents

Similar Documents

Publication Publication Date Title
JP2012526842A5 (cg-RX-API-DMAC7.html)
JP2012503008A5 (cg-RX-API-DMAC7.html)
JP2010510976A5 (cg-RX-API-DMAC7.html)
JP2011518218A5 (cg-RX-API-DMAC7.html)
JP2009533410A5 (cg-RX-API-DMAC7.html)
JP2011519854A5 (cg-RX-API-DMAC7.html)
EP4328223A3 (en) Substituted diaminocarboxamide and diaminocarbonitrile pyrimidines, compositions thereof, and methods of treatment therewith
JP6595078B2 (ja) アミノカルボニルカルバメート化合物
JP2008530099A5 (cg-RX-API-DMAC7.html)
JP2010031025A5 (cg-RX-API-DMAC7.html)
JP2014051526A5 (cg-RX-API-DMAC7.html)
JP2010520341A5 (cg-RX-API-DMAC7.html)
JP2015516420A5 (cg-RX-API-DMAC7.html)
JP2009531277A5 (cg-RX-API-DMAC7.html)
PH12014500775A1 (en) Ethynyl derivatives as mglur5 allosteric modulators
JP2013526610A5 (cg-RX-API-DMAC7.html)
NZ597498A (en) Cyclopropyl amine derivatives as histamin H3 receptor modulators
PH12013501895A1 (en) Ethynyl derivatives as positive allosteric modulators of the mglur5
JP2006521393A5 (cg-RX-API-DMAC7.html)
JP2010502674A5 (cg-RX-API-DMAC7.html)
JP2008525513A5 (cg-RX-API-DMAC7.html)
JP2005538974A5 (cg-RX-API-DMAC7.html)
JP2012521353A5 (cg-RX-API-DMAC7.html)
NO20082436L (no) Forbindelser med medisinske effekter grunnet interaksjonen med glukokortikoidreseptor
JP2010523540A5 (cg-RX-API-DMAC7.html)